Importantly, our results demonstrate that a Tie2 inhibitor Rebastinib (a phase 1b/phase 2 clinical trial drug) ameliorates CCM lesion progression in the mouse CCM models, correlating with normalized EC junction, EC-pericyte interaction, and vascular integrity. The gene discussed is TEK; the disease is cerebral cavernous malformation.